BEIJING, Aug. 26 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.
The studies are co-monitored by the Company and Beijing Zenith International Medical Science and Technology Development Company Limited, a mid-size full-service clinical research organization, and carried out in Peking University Third Hospital, a top-ranked AAA hospital recognized as a base adherence to the principles of good clinical practices (GCPs).
R-Bambuterol(R) Hydrochloride Tablets showed significant efficacy and less toxicity in preclinical trials as an anti-asthma drug than Bambuterol currently available in the market.
If it reaches the market, R-Bambuterol(R) Hydrochloride Tablets would address the Chinese asthma and chronic obstructive pulmonary disease (COPD) market led by AstraZeneca with a 26 percent share in 2009, according to IMS.
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its other filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact: Lotus Pharmaceuticals, Inc. Yan Zeng, CFO Tel: +86-10-6389-9868 Email: firstname.lastname@example.org
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved